{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:06:48Z","timestamp":1787162808267,"version":"build-2736575974"},"posted":{"date-parts":[[2025,5,13]]},"group-title":"In Review","reference-count":65,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,4,25]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <italic>CBFA2T3::GLIS2<\/italic>\n                  fusion positive pediatric acute myeloid leukemia (AML) remains one of the worst prognostic AML subgroups. To uncover innovative targeted therapeutic approaches in this disease subtype we performed genome-scale CRISPR-Cas9 screening that highlighted a strong, selective dependency on\n                  <italic>JAK2<\/italic>\n                  compared to other types of cancer. Using a doxycycline-inducible\n                  <italic>JAK2<\/italic>\n                  knockout (KO) system, we validated\n                  <italic>JAK2<\/italic>\n                  dependency in\n                  <italic>CBFA2T3::GLIS2<\/italic>\n                  cell lines, observing impaired proliferation in vitro and in vivo and induced apoptosis with\n                  <italic>JAK2<\/italic>\n                  KO. Both type I (ruxolitinib) and type II (CHZ868) JAK2 inhibitors showed selective in vitro activity in\n                  <italic>CBFA2T3::GLIS2<\/italic>\n                  positive AML models. To identify resistance and sensitizer mechanisms to JAK2 inhibitors, we used CRISPR-Cas9 ruxolitinib anchor screening in\n                  <italic>CBFA2T3::GLIS2<\/italic>\n                  AML. sgRNAs targeting negative regulators of the MAPK pathway were enriched in the ruxolitinib-treated cells. Similarly,\n                  <italic>CBFA2T3::GLIS2<\/italic>\n                  AML sublines grown to resistance under chronic ruxolitinib treatment expressed pathogenic\n                  <italic>NRAS<\/italic>\n                  mutations. Both approaches converged on MAPK pathway activation as a resistance mechanism to ruxolitinib treatment. Combining ruxolitinib with MEK inhibitors showed a synergistic effect in cell lines and patient-derived xenograft (PDX) cells expressing the fusion and in vivo activity in a\n                  <italic>CBFA2T3::GLIS2<\/italic>\n                  AML PDX, suggesting a potential approach to target this signaling circuitry in this poor outcome AML subtype.\n                <\/p>","DOI":"10.21203\/rs.3.rs-6528748\/v1","type":"posted-content","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T05:46:13Z","timestamp":1747115173000},"source":"Crossref","is-referenced-by-count":1,"title":["Identifying Targeted Therapies for CBFA2T3::GLIS2 Acute Myeloid Leukemia"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1093-351X","authenticated-orcid":false,"given":"Fanny","family":"Gonzales","sequence":"first","affiliation":[{"name":"Geneva University Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Schneider","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5668-6297","authenticated-orcid":false,"given":"Gabriela","family":"Alexe","sequence":"additional","affiliation":[{"name":"Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Lin","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delan","family":"Khalid","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Geneva University Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7664-5030","authenticated-orcid":false,"given":"Allen","family":"Basanthakumar","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Ellegast","sequence":"additional","affiliation":[{"name":"University of Zurich"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Merickel","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvi","family":"Salhotra","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Taillon","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wunderlich","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ansari","sequence":"additional","affiliation":[{"name":"University Hospital of Geneva"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Perry","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Degar","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-0216","authenticated-orcid":false,"given":"Yana","family":"Pikman","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0218-7895","authenticated-orcid":false,"given":"Kimberly","family":"Stegmaier","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3389\/fped.2019.00463","article-title":"Targeted Therapies for Pediatric AML: Gaps and Perspective","volume":"7","author":"Lonetti A","year":"2019","unstructured":"Lonetti A, Pession A, Masetti R. Targeted Therapies for Pediatric AML: Gaps and Perspective. Front Pediatr. 2019;7:463.","journal-title":"Front Pediatr"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood.V97.12.3727","article-title":"Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution\u2019s experience","volume":"97","author":"Athale UH","year":"2001","unstructured":"Athale UH, Razzouk BI, Raimondi SC, Tong X, Behm FG, Head DR, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution\u2019s experience. Blood. 2001;97(12):3727\u201332.","journal-title":"Blood"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/pbc.20951","article-title":"Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children\u2019s Oncology Group","volume":"49","author":"Barnard DR","year":"2007","unstructured":"Barnard DR, Alonzo TA, Gerbing RB, Lange B, Woods WG, Children\u2019s Oncology Group. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2007;49(1):17\u201322.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2012.10.007","article-title":"An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia","volume":"22","author":"Gruber TA","year":"2012","unstructured":"Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, et al. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012;22(5):683\u201397.","journal-title":"Cancer Cell"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccell.2017.02.006","article-title":"ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia","volume":"31","author":"Thirant C","year":"2017","unstructured":"Thirant C, Ignacimouttou C, Lopez CK, Diop M, Le Mou\u00ebl L, Thiollier C, et al. ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell. 2017;31(3):452\u201365.","journal-title":"Cancer Cell"},{"key":"ref6","author":"Bertuccio SN","unstructured":"Bertuccio SN, Boudia F, Cambot M, Lopez CK, Lordier L, Donada A, et al. The Pediatric Acute Leukemia Fusion Oncogene ETO2-GLIS2 Increases Self-Renewal and Alters Differentiation in a Human Induced Pluripotent Stem Cells-Derived Model. HemaSphere [Internet]. 2019 Dec 16 [cited 2021 Mar 2];4(1). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7000481\/"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1158\/2159-8290.CD-18-1463","article-title":"Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia","volume":"9","author":"Lopez CK","year":"2019","unstructured":"Lopez CK, Noguera E, Stavropoulou V, Robert E, Aid Z, Ballerini P, et al. Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia. Cancer Discov. 2019;9(12):1736\u201353.","journal-title":"Cancer Discov"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.3772","article-title":"Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia is Characterized by Distinct Genomic Subsets with Varying Outcomes","volume":"49","author":"Rooij JDE","year":"2017","unstructured":"de Rooij JDE, Branstetter C, Ma J, Li Y, Walsh MP, Cheng J, et al. Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia is Characterized by Distinct Genomic Subsets with Varying Outcomes. Nat Genet. 2017;49(3):451\u20136.","journal-title":"Nat Genet"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.15725","article-title":"CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity","volume":"184","author":"Masetti R","year":"2019","unstructured":"Masetti R, Bertuccio SN, Pession A, Locatelli F. CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity. Br J Haematol. 2019;184(3):337\u201347.","journal-title":"Br J Haematol"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-19-1800","article-title":"Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-positive AML Defines Novel Therapeutic Options \u2013 A COG and TARGET Pediatric AML Study","volume":"26","author":"Smith JL","year":"2020","unstructured":"Smith JL, Ries RE, Hylkema T, Alonzo TA, Gerbing RB, Santaguida MT, et al. Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-positive AML Defines Novel Therapeutic Options \u2013 A COG and TARGET Pediatric AML Study. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(3):726\u201337.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"7","key":"ref11","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1158\/2159-8290.CD-21-0956","article-title":"Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts","volume":"12","author":"Ellegast JM","year":"2022","unstructured":"Ellegast JM, Alexe G, Hamze A, Lin S, Uckelmann HJ, Rauch PJ, et al. Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts. Cancer Discov. 2022;12(7):1760\u201381.","journal-title":"Cancer Discov"},{"key":"ref12","article-title":"An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML","author":"Lin S","year":"2021","unstructured":"Lin S, Larrue C, Scheidegger NK, Seong BKA, Dharia NV, Kuljanin M, et al. An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML. Cancer Discov. 2021;candisc.1851.2020.","journal-title":"Cancer Discov"},{"key":"ref13","article-title":"PDX models of relapsed pediatric AML preserve global gene expression patterns and reveal therapeutic targets","author":"Wunderlich M","year":"2022","unstructured":"Wunderlich M, Chen J, Sexton C, Manning N, Byerly L, O\u2019Brien E, et al. PDX models of relapsed pediatric AML preserve global gene expression patterns and reveal therapeutic targets. bioRxiv. 2022;2022.01.31.478534.","journal-title":"bioRxiv"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench JG","year":"2016","unstructured":"Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34(2):184\u201391.","journal-title":"Nat Biotechnol"},{"issue":"6166","key":"ref15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","article-title":"Genome-scale CRISPR-Cas9 knockout screening in human cells","volume":"343","author":"Shalem O","year":"2014","unstructured":"Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84\u20137.","journal-title":"Science"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers RM","year":"2017","unstructured":"Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49(12):1779\u201384.","journal-title":"Nat Genet"},{"key":"ref17","author":"DepMap","unstructured":"DepMap: The Cancer Dependency Map Project at Broad Institute [Internet]. [cited 2023 Jul 24]. Available from: https:\/\/depmap.org\/portal\/"},{"issue":"8","key":"ref18","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.celrep.2015.02.002","article-title":"An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo","volume":"10","author":"Aubrey BJ","year":"2015","unstructured":"Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O\u2019Connor L, Milla L, et al. An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo. Cell Rep. 2015;10(8):1422\u201332.","journal-title":"Cell Rep"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1158\/0008-5472.CAN-22-2245","article-title":"Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer","volume":"83","author":"Hagel KR","year":"2023","unstructured":"Hagel KR, Arafeh R, Gang S, Arnoff TE, Larson RC, Doench JG, et al. Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. Cancer Res. 2023;83(4):613\u201325.","journal-title":"Cancer Res"},{"issue":"22","key":"ref20","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1093\/nar\/gku936","article-title":"Easy quantitative assessment of genome editing by sequence trace decomposition","volume":"42","author":"Brinkman EK","year":"2014","unstructured":"Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014;42(22):e168.","journal-title":"Nucleic Acids Res"},{"issue":"13","key":"ref21","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2014-01-547760","article-title":"Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms","volume":"123","author":"Bhagwat N","year":"2014","unstructured":"Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, et al. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood. 2014;123(13):2075\u201383.","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou TC","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27\u201355.","journal-title":"Adv Enzyme Regul"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou TC","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621\u201381.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou TC","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440\u20136.","journal-title":"Cancer Res"},{"issue":"9","key":"ref25","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/s41588-018-0191-z","article-title":"Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry","volume":"50","author":"Durbin AD","year":"2018","unstructured":"Durbin AD, Zimmerman MW, Dharia NV, Abraham BJ, Iniguez AB, Weichert-Leahey N, et al. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat Genet. 2018;50(9):1240\u20136.","journal-title":"Nat Genet"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1172\/JCI90793","article-title":"CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2","volume":"128","author":"Chen L","year":"2018","unstructured":"Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, et al. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest. 2018;128(1):446\u201362.","journal-title":"J Clin Invest"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41588-021-00819-w","article-title":"A first-generation pediatric cancer dependency map","volume":"53","author":"Dharia NV","year":"2021","unstructured":"Dharia NV, Kugener G, Guenther LM, Malone CF, Durbin AD, Hong AL, et al. A first-generation pediatric cancer dependency map. Nat Genet. 2021;53(4):529\u201338.","journal-title":"Nat Genet"},{"issue":"22","key":"ref28","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal R","year":"2014","unstructured":"Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123(22):e123\u201333.","journal-title":"Blood"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.12274","article-title":"The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis","volume":"161","author":"Verstovsek S","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol. 2013;161(4):508\u201316.","journal-title":"Br J Haematol"},{"key":"ref30","article-title":"Ruxolitinib for the treatment of myelofibrosis: its clinical potential","volume":"95","author":"Verstovsek S","year":"2012","unstructured":"Verstovsek S, Ostojic, Vrhovac, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag. 2012;95.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","article-title":"FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease","volume":"25","author":"Przepiorka D","year":"2020","unstructured":"Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham LC, et al. FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. The Oncologist. 2020;25(2):e328\u201334.","journal-title":"The Oncologist"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","article-title":"CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms","volume":"28","author":"Meyer SC","year":"2015","unstructured":"Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, et al. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 2015;28(1):15\u201328.","journal-title":"Cancer Cell"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2015.06.005","article-title":"Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia","volume":"28","author":"Wu SC","year":"2015","unstructured":"Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015;28(1):29\u201341.","journal-title":"Cancer Cell"},{"issue":"11","key":"ref34","doi-asserted-by":"crossref","first-page":"eaat3834","DOI":"10.1126\/sciadv.aat3834","article-title":"Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis","volume":"4","author":"Tvorogov D","year":"2018","unstructured":"Tvorogov D, Thomas D, Liau NPD, Dottore M, Barry EF, Lathi M, et al. Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Sci Adv. 2018;4(11):eaat3834.","journal-title":"Sci Adv"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/2159-8290.CD-11-0324","article-title":"Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent","volume":"2","author":"Andraos R","year":"2012","unstructured":"Andraos R, Qian Z, Bonenfant D, Rubert J, Vangrevelinghe E, Scheufler C, et al. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov. 2012;2(6):512\u201323.","journal-title":"Cancer Discov"},{"issue":"10","key":"ref36","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/leu.2016.119","article-title":"A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children\u2019s Oncology Group","volume":"30","author":"Brodersen LE","year":"2016","unstructured":"Brodersen LE, Alonzo T, Menssen A, Gerbing R, Pardo L, Voigt A, et al. A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children\u2019s Oncology Group. Leukemia. 2016;30(10):2077\u201380.","journal-title":"Leukemia"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu X","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif F","year":"2017","unstructured":"Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal CCS. 2017;15(1):23.","journal-title":"Cell Commun Signal CCS"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-020-18925-4","article-title":"Early-onset autoimmunity associated with SOCS1 haploinsufficiency","volume":"11","author":"Hadjadj J","year":"2020","unstructured":"Hadjadj J, Castro CN, Tusseau M, Stolzenberg MC, Mazerolles F, Aladjidi N, et al. Early-onset autoimmunity associated with SOCS1 haploinsufficiency. Nat Commun. 2020;11(1):5341.","journal-title":"Nat Commun"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.3892\/mmr.2017.7384","article-title":"Downregulated SOCS1 expression activates the JAK1\/STAT1 pathway and promotes polarization of macrophages into M1 type","volume":"16","author":"Liang YB","year":"2017","unstructured":"Liang YB, Tang H, Chen ZB, Zeng LJ, Wu JG, Yang W, et al. Downregulated SOCS1 expression activates the JAK1\/STAT1 pathway and promotes polarization of macrophages into M1 type. Mol Med Rep. 2017;16(5):6405\u201311.","journal-title":"Mol Med Rep"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40142-016-0100-7","article-title":"Expansion of the RASopathies","volume":"4","author":"Tidyman WE","year":"2016","unstructured":"Tidyman WE, Rauen KA. Expansion of the RASopathies. Curr Genet Med Rep. 2016;4(3):57\u201364.","journal-title":"Curr Genet Med Rep"},{"issue":"12","key":"ref42","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/ng.3427","article-title":"Recurrent inactivating RASA2 mutations in melanoma","volume":"47","author":"Arafeh R","year":"2015","unstructured":"Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A, et al. Recurrent inactivating RASA2 mutations in melanoma. Nat Genet. 2015;47(12):1408\u201310.","journal-title":"Nat Genet"},{"issue":"31","key":"ref43","doi-asserted-by":"crossref","first-page":"11473","DOI":"10.1073\/pnas.1324128111","article-title":"Next-generation sequencing identifies rare variants associated with Noonan syndrome","volume":"111","author":"Chen PC","year":"2014","unstructured":"Chen PC, Yin J, Yu HW, Yuan T, Fernandez M, Yung CK, et al. Next-generation sequencing identifies rare variants associated with Noonan syndrome. Proc Natl Acad Sci U S A. 2014;111(31):11473\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref44","author":"Drenberg CD","year":"2019","unstructured":"Drenberg CD, Shelat A, Dang J, Cotton A, Orwick SJ, Li M, et al. A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nat Commun [Internet]. 2019 May 16 [cited 2021 Mar 15];10. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6522510\/"},{"issue":"1","key":"ref45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri H","year":"2018","unstructured":"Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24(1):103\u201312.","journal-title":"Nat Med"},{"issue":"11","key":"ref46","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts KG","year":"2014","unstructured":"Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005\u201315.","journal-title":"N Engl J Med"},{"issue":"52","key":"ref47","doi-asserted-by":"crossref","first-page":"89923","DOI":"10.18632\/oncotarget.21027","article-title":"JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia","volume":"8","author":"Steeghs EMP","year":"2017","unstructured":"Steeghs EMP, Jerchel IS, de Goffau-Nobel W, Hoogkamer AQ, Boer JM, Boeree A, et al. JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia. Oncotarget. 2017;8(52):89923\u201338.","journal-title":"Oncotarget"},{"issue":"9","key":"ref48","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"Levine RL","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7(9):673\u201383.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"ref49","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/2159-8290.CD-22-0952","article-title":"Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms","volume":"14","author":"Dunbar AJ","year":"2024","unstructured":"Dunbar AJ, Bowman RL, Park YC, O\u2019Connor K, Izzo F, Myers RM, et al. Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms. Cancer Discov. 2024;14(5):737\u201351.","journal-title":"Cancer Discov"},{"issue":"10","key":"ref50","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/pbc.25575","article-title":"A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children\u2019s Oncology Group phase 1 consortium study (ADVL1011)","volume":"62","author":"Loh ML","year":"2015","unstructured":"Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, et al. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children\u2019s Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015;62(10):1717\u201324.","journal-title":"Pediatr Blood Cancer"},{"issue":"Supplement 1","key":"ref51","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1182\/blood-2022-164699","article-title":"A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521\/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations","volume":"140","author":"Tasian SK","year":"2022","unstructured":"Tasian SK, Hunter DS, Chen IML, Harvey RC, Carroll AJ, Wagner E, et al. A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521\/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations. Blood. 2022;140(Supplement 1):6117\u20138.","journal-title":"Blood"},{"issue":"4","key":"ref52","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","article-title":"Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review","volume":"62","author":"Appeldoorn TYJ","year":"2023","unstructured":"Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL de, Touw DJ. Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review. Clin Pharmacokinet. 2023;62(4):559\u201371.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"ref53","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1097\/HS9.0000000000000562","article-title":"Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial","volume":"5","author":"Harrison CN","year":"2021","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, et al. Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. HemaSphere. 2021;5(5):e562.","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"ref54","doi-asserted-by":"crossref","first-page":"3147.1","DOI":"10.1182\/blood-2024-193905","article-title":"A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)","volume":"144","author":"Mascarenhas JO","year":"2024","unstructured":"Mascarenhas JO, Borate U, Bose P, Byrd JC, Garcia JS, Grunwald MR, et al. A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i). Blood. 2024;144(Supplement 1):3147.1.","journal-title":"Blood"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26731","article-title":"Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes","volume":"97","author":"Rivera D","year":"2022","unstructured":"Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, et al. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022;97(12):1599\u2013606.","journal-title":"Am J Hematol"},{"issue":"2","key":"ref56","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/2159-8290.CD-19-0209","article-title":"Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia","volume":"10","author":"Cremer A","year":"2020","unstructured":"Cremer A, Ellegast JM, Alexe G, Frank ES, Ross L, Chu SH, et al. Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia. Cancer Discov. 2020;10(2):214\u201331.","journal-title":"Cancer Discov"},{"issue":"5","key":"ref57","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/bloodadvances.2020003398","article-title":"Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib","volume":"5","author":"Peretz CAC","year":"2021","unstructured":"Peretz CAC, McGary LHF, Kumar T, Jackson H, Jacob J, Durruthy-Durruthy R, et al. Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. Blood Adv. 2021;5(5):1437.","journal-title":"Blood Adv"},{"issue":"2","key":"ref58","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","article-title":"Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors","volume":"2","author":"Alotaibi AS","year":"2021","unstructured":"Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, et al. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021;2(2):125\u201334.","journal-title":"Blood Cancer Discov"},{"issue":"26","key":"ref59","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2014-05-574582","article-title":"Preclinical efficacy of MEK inhibition in Nras-mutant AML","volume":"124","author":"Burgess MR","year":"2014","unstructured":"Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, et al. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 2014;124(26):3947\u201355.","journal-title":"Blood"},{"issue":"10378","key":"ref60","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"Langen AJ","year":"2023","unstructured":"de Langen AJ, Johnson ML, Mazieres J, Dingemans AMC, Mountzios G, Pless M, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. The Lancet. 2023;401(10378):733\u201346.","journal-title":"The Lancet"},{"issue":"18","key":"ref61","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1200\/JCO.22.02524","article-title":"Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non\u2013Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100","volume":"41","author":"Dy GK","year":"2023","unstructured":"Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, et al. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non\u2013Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. J Clin Oncol. 2023;41(18):3311\u20137.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"ref62","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2021.39.15_suppl.3007","article-title":"A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion","volume":"39","author":"Shin SJ","year":"2021","unstructured":"Shin SJ, Lee J, Kim TM, Kim JS, Kim YJ, Hong YS, et al. A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion. J Clin Oncol. 2021;39(15_suppl):3007\u20133007.","journal-title":"J Clin Oncol"},{"issue":"4","key":"ref63","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI98785","article-title":"Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms","volume":"129","author":"Stivala S","year":"2019","unstructured":"Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, et al. Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019;129(4):1596\u2013611.","journal-title":"J Clin Invest"},{"issue":"6","key":"ref64","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1172\/JCI74182","article-title":"Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm","volume":"124","author":"Kong G","year":"2014","unstructured":"Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, et al. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. J Clin Invest. 2014;124(6):2762\u201373.","journal-title":"J Clin Invest"},{"issue":"22","key":"ref65","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.1182\/bloodadvances.2022008503","article-title":"Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1\u2013antibody-drug conjugate","volume":"6","author":"Tang T","year":"2022","unstructured":"Tang T, Le Q, Castro S, Pardo L, McKay CN, Perkins L, et al. Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1\u2013antibody-drug conjugate. Blood Adv. 2022;6(22):5933\u20137.","journal-title":"Blood Adv"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6528748\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6528748\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:08:23Z","timestamp":1767946103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6528748\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":65,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-6528748\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41375-025-02845-7","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,5,13]]},"subtype":"preprint"}}